Efficacy and safety of long-acting GnRH agonists inin vitrofertilization and embryo transfer
- 1 January 2001
- journal article
- research article
- Published by Taylor & Francis Ltd in Human Fertility
- Vol. 4 (2), 85-93
- https://doi.org/10.1080/1464727012000199351
Abstract
The introduction of gonadotrophin-releasing hormone (GnRH) agonists combined with gonadotrophins is considered to be one of the most significant events in the development of in vitro fertilization and embryo transfer (IVF-ET) programmes. This article reviews the use of GnRH agonists in IVF-ET programmes and the efficacy and safety of long-acting GnRH agonists. The use of agonists results in higher clinical pregnancy rates, more supernumerary embryos for cryopreservation and allows convenient programming of oocyte recovery. There are different types of agonist and ovarian stimulation protocol available for clinical use. Recent meta-analysis of the Cochrane database has demonstrated the superiority of the long protocols over the short and ultra-short protocols for GnRH agonist use in IVF and GIFT. The depot injection offers increased clinical and patient compliance and improves efficacy of pituitary downregulation. However, compared with short-acting agonists, the depot preparations are associated with a longer period of stimulation and higher doses of gonadotrophins. To date, there is no evidence of an increased risk of pregnancy wastages or teratogenicity in human pregnancies exposed to long-acting agonists.Keywords
This publication has 60 references indexed in Scilit:
- Should we still advise infertile couples to use (barrier) contraception before IVF down-regulation?Fertility and Sterility, 2000
- A crossover study of triptorelin and leuprorelin acetateFertility and Sterility, 2000
- Long-term down-regulation does not improve pregnancy rates in an in vitro fertilization programFertility and Sterility, 1998
- Outcome of pregnancies inadvertently exposed to gonadotropin-releasing hormone analogues (GnRH-a) in early gestationJournal of Assisted Reproduction and Genetics, 1993
- Menotropin stimulation after prolonged gonadotropin releasing hormone agonist pretreatment for in vitro fertilization in patients with endometriosisJournal of Assisted Reproduction and Genetics, 1992
- The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (Buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF)Journal of Assisted Reproduction and Genetics, 1991
- High fecundity of amenorrhoeic women in embryo-transfer programmesThe Lancet, 1991
- The use of the GnRH analogue buserelin for IVF—does it improve fertility?BJOG: An International Journal of Obstetrics and Gynaecology, 1991
- Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormoneBMJ, 1988
- BIRTH AFTER THE REIMPLANTATION OF A HUMAN EMBRYOThe Lancet, 1978